- Home
- MAKO vs APMD Comparison
MAKO vs APMD Comparison
Compare MAKO & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MAKO | APMD |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Canada | United States |
| Employees | 30 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.6M | 895.5M |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | MAKO | APMD |
|---|---|---|
| Price | $8.69 | $18.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $50.33 |
| AVG Volume (30 Days) | 101.2K | ★ 427.0K |
| Earning Date | 11-15-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $76.73 | $136.17 |
| Revenue Next Year | $0.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.58 | $16.43 |
| 52 Week High | $11.10 | $35.29 |
Technical Indicators
Market Signals| Indicator | MAKO | APMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.39 | 42.25 |
| Support Level | $8.43 | $17.38 |
| Resistance Level | $10.64 | $20.00 |
| Average True Range (ATR) | 0.31 | 1.65 |
| MACD | -0.04 | 0.12 |
| Stochastic Oscillator | 26.39 | 37.73 |
Price Performance
Historical ComparisonAbout MAKO Mako Mining Corp Common Stock
Mako Mining Corp is a gold mining, development, and exploration firm. The companies primary asset is the San Albino mine, an open-pit mine located in Nicaragua. In addition to its mining operation, the company continues to explore its other concessions in Nicaragua and Guyana.
About APMD Apnimed Inc. Common Stock
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).